Literature DB >> 28349222

Anticoagulation therapy for a LVAD patient with acquired warfarin resistance.

Daisuke Yoshioka1, Koichi Toda1, Takayuki Hidaka2, Soichiro Yasuda3, Shunsuke Saito1, Keitaro Domae1, Yoshiki Sawa4.   

Abstract

Anticoagulation therapy with warfarin is essential for postoperative management in patients with left ventricular assist device (LVAD). In this manuscript, we report the case of a patient who developed warfarin resistance after LVAD implantation. Although we administered a novel anticoagulant drug in addition to warfarin and aspirin therapy, the patient developed a major stroke. The patient needed continuous intravenous heparinization until heart transplantation for approximately 2 years. Meticulous management of anticoagulation therapy is essential for a LVAD with warfarin resistance. To our best knowledge, our case is the first case of warfarin resistance in a patient with LVAD.

Entities:  

Keywords:  Anticoagulation therapy; Left ventricular assist device; Warfarin

Mesh：

Substances：

Year:  2017        PMID： 28349222     DOI： 10.1007/s10047-017-0947-8

Source DB:  PubMed          Journal:  J Artif Organs        ISSN： 1434-7229            Impact factor:   1.731


  7 in total

1.  A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.

Authors:  Ronen Loebstein; Ilana Dvoskin; Hillel Halkin; Manuela Vecsler; Aharon Lubetsky; Gideon Rechavi; Ninette Amariglio; Yoram Cohen; Gie Ken-Dror; Shlomo Almog; Eva Gak
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve.

Authors:  Katie E O' Sullivan; Brendan Meany; John P Hurley
Journal:  Int J Cardiol       Date:  2015-04-07       Impact factor: 4.164

3.  National trends and outcomes in device-related thromboembolic complications and malfunction among heart transplant candidates supported with continuous-flow left ventricular assist devices in the United States.

Authors:  Omar Wever-Pinzon; Yoshifumi Naka; Arthur R Garan; Koji Takeda; Stephen Pan; Hiroo Takayama; Donna M Mancini; Paolo Colombo; Veli K Topkara
Journal:  J Heart Lung Transplant       Date:  2016-03-11       Impact factor: 10.247

4.  Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device.

Authors:  John V Terrovitis; Argyrios Ntalianis; Chris J Kapelios; Styliani Vakrou; Nikolaos Diakos; Lambros Katsaros; Michalis Tsamatsoulis; Elisabeth Kaldara; Christos Charitos; John N Nanas
Journal:  Hellenic J Cardiol       Date:  2015 Jan-Feb

5.  Early mechanical mitral valve thrombosis in a patient with warfarin resistance.

Authors:  Ayse Saatci Yasar; Yucel Balbay; Orhan Maden; Hatice Sasmaz
Journal:  J Heart Valve Dis       Date:  2007-03

6.  Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices.

Authors:  Veli K Topkara; Robert J Knotts; Douglas L Jennings; A Reshad Garan; Allison P Levin; Alexander Breskin; Francesco Castagna; Barbara Cagliostro; Melana Yuzefpolskaya; Koji Takeda; Hiroo Takayama; Nir Uriel; Donna M Mancini; Andrew Eisenberger; Yoshifumi Naka; Paolo C Colombo; Ulrich P Jorde
Journal:  ASAIO J       Date:  2016 Sep-Oct       Impact factor: 2.872

7.  Intravenous warfarin as an alternative for anticoagulation.

Authors:  Rochelle M Gellatly
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705
  7 in total
  1 in total

Review 1.  Journal of Artificial Organs 2017: the year in review : Journal of Artificial Organs Editorial Committee.

Authors:  Y Sawa; G Matsumiya; K Matsuda; E Tatsumi; T Abe; K Fukunaga; S Ichiba; A Kishida; K Kokubo; T Masuzawa; A Myoui; M Nishimura; T Nishimura; T Nishinaka; E Okamoto; S Tokunaga; T Tomo; T Tsukiya; Y Yagi; T Yamaoka
Journal:  J Artif Organs       Date:  2018-02-09       Impact factor: 1.731
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.